Genmab Announces Upcoming Ofatumum... ( Front Line CLL NHL and CLL Retreatm...)

Genmab Announces Upcoming Ofatumumab Studies

Date:8/25/2008

Front Line CLL, NHL and CLL Retreatment and Japanese Development Studies

Planned

COPENHAGEN, Denmark, August 25 /PRNewswire-FirstCall/ -- Genmab has announced plans to begin four studies of ofatumumab in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

Genmab A/S (OMX: GEN) announced today plans to begin four studies of ofatumumab in chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin's lymphoma (NHL) this year.

"Genmab and GSK have worked diligently to expand the ofatumumab development program to maximize the value of the antibody for patients and shareholders since our collaboration began," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab."The new studies we are initiating this year will examine the potential of ofatumumab in Japan as well as a number of new treatment settings - retreatment, maintenance and front line with chlorambucil."

Phase III CLL front line chlorambucil combination This open-label, parallel-arm study will include 444 patients with previously untreated CLL.Patients in the study will be randomized to receive ofatumumab in combination with chlorambucil or chlorambucil alone.Patients receiving ofatumumab in combination with chlorambucil will receive one infusion of ofatumumab at 300 mg, one infusion at 1000 mg a week later, followed by up to 11 monthly infusions at 1000 mg.Patients will be evaluated for disease status one month following last treatment then every 3 months for 5 years.

The primary objective of the study is to evaluate the progression free survival of ofatumumab in combination with chlorambucil therapy versus chlorambucil therapy alone for the treatment of front line CLL.

Phase II CLL ofatumumab retreatment and maintenance treatment study This study will examine the retreatment and maintenance treatment of refractory CLL patients who participated in the ongoing Phase III CLL study and had disease progression following
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4
Related medicine technology :

1. DAHANCA Initiates Head and Neck Cancer Study With Genmabs HuMax-EGFr
2. Bionomics Achieves US$1 Million Milestone Payment from Genmab
3. Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
4. Genmab Announces Updates on Phase III Cancer Studies
5. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
6. Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer
7. Genmab Reaches Milestone in Ofatumumab Collaboration
8. Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study
9. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer

Post Your Comments:

(Date:5/21/2013)... May 21, 2013 Reportlinker.com announces ... available in its catalogue: ... for Optical Coherence Tomography (OCT) ... STUDY OBJECTIVES ... to offer synopsis of the current and ...

(Date:5/21/2013)... , May 21, 2013 Janssen R&D ... results from the global Phase 3 PROMISE study ... simeprevir (TMC435) led to sustained virologic response 12 ... 79 percent of treatment-experienced genotype 1 chronic hepatitis ... all stages of liver fibrosis, when administered once ...

(Date:5/21/2013)... , May 21, 2013 U.S. spending on ... complex diseases such as cancer, multiple sclerosis and rheumatoid ... the end of 2015, according to a forecast released ... (Logo: http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) "As we ... and health plans to act so they can continue ...

[0] Global Markets and Technologies for Optical Coherence Tomography (OCT)[0] Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients [0] U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015

... May 4 Roche Public Affairs Director Stacy Quinn ... Star by the Healthcare Businesswomen,s Association (HBA) at the organization,s annual awards luncheon ... , , ... for detail and has earned the appreciation and respect of the management team, ...

... In conjunction with DURECT Corporation,s (Nasdaq: DRRX ) first quarter 2010 ... will be broadcast live over the internet on Monday, May 10, 2010 ... , , ... , , ...

Cached Medicine Technology:Roche's Quinn Honored as 2010 HBA Rising Star 2 Roche's Quinn Honored as 2010 HBA Rising Star 3 DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call 2

Roche's Quinn Honored as 2010 HBA Rising Star DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call

(Date:5/21/2013)... Daily Gossip Magazine published well-documented articles that are meant to ... on the latest weight loss methods by publishing weekly in-depth ... review of Kyle Leon’s Customized Fat Loss Plan ... lose weight or stay in shape with the minimum effort. ... by a popular fitness trainer, Kyle Leon, who has made ...

(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker Waichman ... of victims injured by defective medical devices, is offering remarks ... case of the Estate of Fred E. Taylor v. Intuitive ... Orchard). A May 21, 2013, Bloomberg report noted ... acted like a “car dealership” in how it deployed its ...

(Date:5/21/2013)... 2013 Parker Waichman LLP, a national ... injured by defective medical devices, is addressing new research ... on May 15, 2013. The study found that magnetic ... that occur in patients with metal-on-metal hip implants even ... ) , “We’ve known for quite ...

(Date:5/21/2013)... One-year results from SOURCE XT one of the ... reported today at EuroPCR 2013 show good clinical ... device success for all access approaches, valve sizes and ... up 2688 consecutively enrolled patients (mean age 81.5 years) ... 93 centres in 17 countries between July 2010 and ...

(Date:5/21/2013)... (PRWEB) May 21, 2013 The federal ... hip replacement lawsuits in U.S. District Court, ... response to a request from Plaintiffs’ Counsel to conduct ... The May 17th Order grants that request, and ... conducted. (In re: Wright Medical Technology, Inc., Conserve Hip ...

Breaking Medicine News(10 mins):Health News:Customized Fat Loss Plan Review and Diet Secrets Revealed By Daily Gossip Magazine 2 Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 2 Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 3 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3 Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2 Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3

[0] Customized Fat Loss Plan Review and Diet Secrets Revealed By Daily Gossip Magazine [0] Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership [0] Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants [0] Post-approval TAVI registry shows high rates of device success at 1 year [0] Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation

... Based on finding of a recent study researchers say ... day is an effective preventive // measure for people ... anti-epileptic drug. Studies have also shown its success in ... neuralgia, and migraine headache. Since gabapentin often reduces migraines ...

... study reports that kids with asthma are more likely to ... moving or family relationships. // ,60 children who had ... had a history of chronic stress. Over 18 months, kids ... flow tests, which measured their breathing strength. Both kids and ...

... do much to relieve knee pain associated with osteoarthritis, ... studies comparing the drugs to placebos. ,The ... and around 3,000 received placebos. The average age of ... been experiencing symptoms for about eight years. Since long-term ...

... fatigue but can also be dangerous. In some cases ... hours can cause deep-vein thrombosis, a potentially serious condition ... pelvic veins. , ,The risk is greatest for ... cardiovascular disease, cancer and blood-clotting disorders, according to the ...

... could lead to an enlarged heart by early adulthood, ... .// ,Researchers followed 467 children for almost ... participants at childhood with data obtained at young adulthood. ... size. Participants who had the highest BMI levels in ...

... who take high doses of steroids are more than twice ... not, say researchers based on findings of a recent study. ... the skin, lungs, joints, digestive tract, such as asthma, inflammatory ... health records of 68,781 people who used steroids between 1993 ...

Cached Medicine News:

Another Use For Epilepsy Drugs Stress A Precursors Of Asthma In Kids The Effectiveness Of NSAIDs Evaluated Travel in Aircraft can cause Thrombosis The Risks Of Childhood Weight Gain The Link Between High-dose Steroid Use And Heart Disease Questioned

Sensitive Eyes drops keep soft contact lenses moist....

Lens Plus Sterile Saline Solution...

... Renu Multiplus No Rub formula is the ... today. All steps in one bottle without ... stores soft contact lenses and removes protein ... multi-purpose solution that contains Hydranate, a special ...

Sensitive Eyes sterile saline spray is the preservative-free aerosol saline solution for people with eyes sensitive to preservatives. Used for rinsing soft contact lenses after cleaning or thermal or...

Medicine Products:

Sensitive Eyes Drops Lens Plus Sterile Saline Solution Renu MultiPlus Multi-Purpose Solution No Rub Formula Sensitive Eyes Sterile Saline Spray